Vitiligo Clinical Trial
Official title:
Fractional Laser Abrasion in Combination With UVB Therapy in Vitiligo Patients: a Randomized Controlled Study.
Rationale: Vitiligo is a common skin disorder that can impair a patient's quality of life.
Many depigmented lesions in vitiligo patients remain therapy resistant for medical
treatment. Therefore new therapeutic options in these patients are necessary. Currently,
dermabrasion by conventional or fractional laser therapy in combination with NB-UVB therapy
and steroids appears to be effective in therapy resistant areas. However, little literature
on this combination is available.
Objectives: To assess the efficacy and patient safety of (1)fractional CO2-laser treatment
in combination with NB- UVB,(2) fractional CO2-laser treatment in combination with NB- UVB
and topical corticosteroids versus NB-UVB treatment alone(3) Study design: Prospective
observer blinded randomised intra-patient controlled study.
Study population: 23 patients ≥ 18 years with non segmental vitiligo who receive NB-UVB
treatment at the Netherlands Institute for Pigment Disorders (SNIP) at the Academic Medical
Centre University of Amsterdam. We will include patients with 3 depigmented lesions that are
resistant to NB- UVB treatment after 3 to 6 months.
Methods: Three NB-UVB resistant depigmented regions on the trunk or extremities will be
randomly allocated to;(1) NB-UVB treatment in combination with fractional CO2 laser
abrasion, or (2) NB-UVB treatment in combination with fractional CO2 laser abrasion and
topical steroids, or (3) NB-UVB treatment alone. NB-UVB treatment and topical steroids will
be given according to the standard treatment protocol of the SNIP and continued for at least
6 months. Two and 6 months after the laser treatment, the percentage of repigmentation of
the lesions will be assessed.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05298033 -
Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo
|
Phase 2 | |
| Recruiting |
NCT05872477 -
Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas
|
Phase 2 | |
| Terminated |
NCT04374435 -
Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo
|
N/A | |
| Completed |
NCT04103060 -
Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo
|
Phase 2 | |
| Terminated |
NCT04271501 -
Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions
|
N/A | |
| Completed |
NCT04530344 -
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
|
Phase 3 | |
| Not yet recruiting |
NCT05008887 -
Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo
|
Phase 4 | |
| Terminated |
NCT02191748 -
Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo
|
Phase 2/Phase 3 | |
| Terminated |
NCT01262547 -
A New Micrografting Technique for Vitiligo
|
Phase 2 | |
| Completed |
NCT01382589 -
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo
|
Phase 2 | |
| Active, not recruiting |
NCT04971200 -
Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo
|
Early Phase 1 | |
| Completed |
NCT04872257 -
Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo
|
N/A | |
| Completed |
NCT04547998 -
Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
|
N/A | |
| Not yet recruiting |
NCT04039451 -
Prevalence of Psoriasis and Vitiligo in Assiut Governorate, Egypt
|
||
| Not yet recruiting |
NCT03611348 -
Microneedling and Latanoprost in Acrofacial Vitiligo
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03199664 -
Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo
|
Phase 4 | |
| Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
| Completed |
NCT03249064 -
Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo
|
N/A | |
| Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Recruiting |
NCT04246372 -
Tofacitinib for Immune Skin Conditions in Down Syndrome
|
Phase 2 |